Reappraising Cladophialophora bantiana phaeohyphomycosis in France: retrospective nation-based study.


Journal

The Lancet. Microbe
ISSN: 2666-5247
Titre abrégé: Lancet Microbe
Pays: England
ID NLM: 101769019

Informations de publication

Date de publication:
09 Oct 2024
Historique:
received: 25 03 2024
revised: 05 05 2024
accepted: 23 05 2024
medline: 13 10 2024
pubmed: 13 10 2024
entrez: 12 10 2024
Statut: aheadofprint

Résumé

Cladophialophora bantiana is one of the most virulent phaeohyphomycetes, typically causes non-angiogenic single (or sometimes multiple) cystic brain lesions, and has resulted in a mortality rate of up to 70%. Most C bantiana cases are described either in a series of isolated reports or in very small cohorts. The aim of this retrospective nation-based study was to share the data on C bantiana phaeohyphomycosis cases reported in France and French overseas territories over the past two decades to improve understanding of this disease. Patients with C bantiana infection were processed through the active surveillance programme of invasive fungal infections launched by the National Reference Center for Mycoses and Antifungals, Institut Pasteur (Paris, France), and the French Surveillance Network of Invasive Fungal Infections, which involved 29 hospitals from mainland France and overseas French territories. Only proven and probable cases of infection, according to the revised and updated consensus definitions from the European Organization for Research and Treatment of Cancer and Mycoses Study Group, were included in the study. Patients were diagnosed or confirmed, or both, using a polyphasic approach at the Institut Pasteur between 2002 and 2022. Patients were separated into two groups: those with CNS involvement and those with no CNS involvement. The primary outcome was the survival rate. A total of 23 patients with a C bantiana invasive infection were included during the study period (Jan 1, 2002, to Dec 31, 2022). The median age was 56 years in the CNS involvement group and 65 years in the non-CNS involvement group. Until 2021, the annual number of cases varied between zero and two, with six cases observed in 2022, the warmest year recorded in France since 1900. CNS involvement was observed in 15 (65%) patients, including three disseminated cases; skin and soft tissue involvement in seven (30%) patients and an isolated lung infection in one case. Diabetes was observed in five patients, and any immunodepression factor was observed in 14 (61%) of 23 patients. When considering only patients with CNS involvement, 9-month survival appeared higher in patients who underwent exeresis or large drainage (three [75%] of four patients vs three [27%] of 11 patients; p=0·24) and significantly higher in those treated for 2 or more weeks with triple antifungal therapy (liposomal amphotericin B plus posaconazole and flucytosine; seven [78%] of nine patients vs one [17%] of six patients; p=0·040). Two patients were treated with excision surgery alone (one patient with success, and the other patient lost to follow-up). This study shows that the clinical presentations and underlying medical conditions of C bantiana infections are more diverse than previously described. It also emphasises a significant difference in mortality rate between those with and without CNS involvement. The prognosis improved when surgery was performed and triple antifungal therapy was administered. Such rare and devastating invasive fungal infections should be managed by a multidisciplinary team. Santé Publique France.

Sections du résumé

BACKGROUND BACKGROUND
Cladophialophora bantiana is one of the most virulent phaeohyphomycetes, typically causes non-angiogenic single (or sometimes multiple) cystic brain lesions, and has resulted in a mortality rate of up to 70%. Most C bantiana cases are described either in a series of isolated reports or in very small cohorts. The aim of this retrospective nation-based study was to share the data on C bantiana phaeohyphomycosis cases reported in France and French overseas territories over the past two decades to improve understanding of this disease.
METHODS METHODS
Patients with C bantiana infection were processed through the active surveillance programme of invasive fungal infections launched by the National Reference Center for Mycoses and Antifungals, Institut Pasteur (Paris, France), and the French Surveillance Network of Invasive Fungal Infections, which involved 29 hospitals from mainland France and overseas French territories. Only proven and probable cases of infection, according to the revised and updated consensus definitions from the European Organization for Research and Treatment of Cancer and Mycoses Study Group, were included in the study. Patients were diagnosed or confirmed, or both, using a polyphasic approach at the Institut Pasteur between 2002 and 2022. Patients were separated into two groups: those with CNS involvement and those with no CNS involvement. The primary outcome was the survival rate.
FINDINGS RESULTS
A total of 23 patients with a C bantiana invasive infection were included during the study period (Jan 1, 2002, to Dec 31, 2022). The median age was 56 years in the CNS involvement group and 65 years in the non-CNS involvement group. Until 2021, the annual number of cases varied between zero and two, with six cases observed in 2022, the warmest year recorded in France since 1900. CNS involvement was observed in 15 (65%) patients, including three disseminated cases; skin and soft tissue involvement in seven (30%) patients and an isolated lung infection in one case. Diabetes was observed in five patients, and any immunodepression factor was observed in 14 (61%) of 23 patients. When considering only patients with CNS involvement, 9-month survival appeared higher in patients who underwent exeresis or large drainage (three [75%] of four patients vs three [27%] of 11 patients; p=0·24) and significantly higher in those treated for 2 or more weeks with triple antifungal therapy (liposomal amphotericin B plus posaconazole and flucytosine; seven [78%] of nine patients vs one [17%] of six patients; p=0·040). Two patients were treated with excision surgery alone (one patient with success, and the other patient lost to follow-up).
INTERPRETATION CONCLUSIONS
This study shows that the clinical presentations and underlying medical conditions of C bantiana infections are more diverse than previously described. It also emphasises a significant difference in mortality rate between those with and without CNS involvement. The prognosis improved when surgery was performed and triple antifungal therapy was administered. Such rare and devastating invasive fungal infections should be managed by a multidisciplinary team.
FUNDING BACKGROUND
Santé Publique France.

Identifiants

pubmed: 39395429
pii: S2666-5247(24)00139-3
doi: 10.1016/S2666-5247(24)00139-3
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

100907

Informations de copyright

Copyright © 2024. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of interests We declare no competing interests.

Auteurs

Olivier Lortholary (O)

Institut Pasteur, Paris Cité University, National Reference Center for Invasive Mycoses and Antifungals, Translational Mycology Research Group, Mycology Department, Paris, France; Paris Cité University, Necker-Enfants Malades University Hospital, Necker-Pasteur Center for Infectious Diseases and Tropical Medicine, Assistance Publique-Hôpitaux de Paris, Institut Hospitalo Universitaire Imagine, Paris, France. Electronic address: olivier.lortholary@pasteur.fr.

Dea Garcia-Hermoso (D)

Institut Pasteur, Paris Cité University, National Reference Center for Invasive Mycoses and Antifungals, Translational Mycology Research Group, Mycology Department, Paris, France.

Aude Sturny-Leclère (A)

Institut Pasteur, Paris Cité University, National Reference Center for Invasive Mycoses and Antifungals, Translational Mycology Research Group, Mycology Department, Paris, France.

Karine Sitbon (K)

Institut Pasteur, Paris Cité University, National Reference Center for Invasive Mycoses and Antifungals, Translational Mycology Research Group, Mycology Department, Paris, France.

Céline Nourrisson (C)

Service Parasitologie-Mycologie Centre de Biologie, Hôpital Gabriel Montpied, Clermont-Ferrand, France.

Valérie Letscher-Bru (V)

Université de Strasbourg, UR 3073 Pathogens-Host-Arthropods-Vectors Interactions, Instituts de Bactériologie et de Parasitologie de la Faculté de Médecine, Strasbourg, France; Centre Hospitalier Régional Universitaire de Strasbourg, Plateau Technique de Microbiologie, Laboratoire de Parasitologie et Mycologie Médicale, Strasbourg, France.

Nicole Desbois-Nogard (N)

Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire de la Martinique, Fort-de-France, France.

Ferouze Bani-Sadr (F)

Department of Infectious Diseases, University Hospital of Reims, Reims, France.

Frédéric Bastides (F)

Centre Hospitalo-Universitaire Régional de Tours, Department of Infectious Diseases, Bretonneau University Hospital of Tours, Tours, France.

Boris Bienvenu (B)

Department of Internal Medicine, Hôpital Saint Joseph, Marseille, France.

Camille Cordier (C)

Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Lille, Lille, France.

Anne Coste (A)

Service de Maladies Infectieuses et Tropicales, Hôpital de la Cavale Blanche, Centre Hospitalier Universitaire de Brest, Brest, France; Laboratoire de Traitement de l'Information Médicale, Université de Bretagne Occidentale, Brest, France.

François Danion (F)

Hôpitaux Universitaires de Strasbourg, Service de Maladies Infectieuses et Tropicales, Strasbourg, France; Université de Strasbourg, Laboratoire d'Immuno-Rhumatologie Moléculaire, Institut National de la Santé et de la Recherche Médicale S 1109, Strasbourg, France.

Tristan Dégot (T)

Respiratory Medicine and Lung Transplantation, Strasbourg University Hospital, Strasbourg, France.

David Delarbre (D)

Service de Médecine Interne, Hôpital d'Instruction des Armées Sainte-Anne, Toulon, France.

Arnaud Fekkar (A)

Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier La Pitié-Salpêtrière, Parasitologie Mycologie, Paris, France; Sorbonne Université, Inserm, Centre National de la Recherche Scientifique, Centre d'Immunologie et des Maladies Infectieuses Cimi-Paris, Paris, France.

Christophe Garcie (C)

Laboratoire Commun de Biologie du Groupement Hospitalier de Territoire Béarn & Soule Centre Hospitalier de Pau, Pau, France.

Cyril Garrouste (C)

Department of Nephrology, Hôpital Gabriel-Montpied, Clermont-Ferrand, France.

Maud Gits-Muselli (M)

Service de Microbiologie, Centre National de Référence Associé Escherichia Coli, Hôpital Robert-Debré, Assistance Publique-Hôpitaux de Paris, Paris, France; Université Paris Cité, Infection Antimicrobials Modelling Evolution, Institut National de la Santé et de la Recherche Médicale, Paris, France.

Emilie Guemas (E)

Parasitology-Mycology Department of Toulouse University Hospital, Toulouse, France; Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5051, Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1291, Université Paul Sabatier, Toulouse, France.

Antoine Huguenin (A)

Université de Reims Champagne Ardenne, EpidémioSurveillance et Circulation de Parasites dans les Environnements - UR 7510 Equipe d'Accueil 510, Reims, France; Laboratoire de Parasitologie-Mycologie, Pôle de Biologie Pathologie, Centre Hospitalier Universitaire de Reims, Rue du Général Koening, Reims, France.

Frédéric Janvier (F)

Service de Microbiologie et Hygiène Hospitalière, Hôpital d'Instruction des Armées Sainte-Anne, Toulon et Ecole du Val-de-Grâce, Paris, France.

Nassim Kamar (N)

Transplantation, Toulouse University Hospital, Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1291, Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Université Paul Sabatier, Toulouse, France.

Cyril Kervinio (C)

Service de Gériatrie, Centre Hospitalier François Mitterrand, Pau, France.

Solène Le Gal (S)

Centre Hospitalier Régional Universitaire Hôpital de la Cavale Blanche, Brest, France; Université d'Angers, Infections Respiratoires Fongiques, Brest, France.

Olivier Lesens (O)

Service de Médecine Interne, Hôpital Gabriel-Montpied, Clermont-Ferrand, France.

Marie Machouart (M)

Laboratoire Stress Immunité Pathogènes, EA7300, Faculté de Médecine, Vandoeuvre-les-Nancy, France; Service de Parasitologie-Mycologie, Centre Hospitalier Régional Universitaire de Nancy, Hôpitaux de Brabois, Nancy, France.

Florence Persat (F)

UR3738 Centre pour l'lnnovation en Cancérologie de Lyon, Team Inflammation and Immunity of the Respiratory Epithelium, Claude Bernard University-Lyon 1, Pierre Bénite, France; Department of Medical Mycology and Parasitology, Institute of Infectious Agents, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France.

Sandrine Picot (S)

Bacteriologie, Centre Hospitalier Universitaire Sud Réunion, Saint-Pierre, France.

Anahita Rouze (A)

Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Centre Hospitalier Universitaire Lille, Unité Mixte de Recherche 8576 - U1285 - Unité de Glycobiologie Structurale et Fonctionnelle, Lille, France; Service de Médecine Intensive - Réanimation, Université de Lille, Lille, France.

Stéphane Ranque (S)

Institut Hospitalo-Universitaire, Méditerranée Infection, Marseille, France.

Yvon Ruch (Y)

Hôpitaux Universitaires de Strasbourg, Department of Tropical and Infectious Diseases, Nouvel Hôpital Civil, Strasbourg, France.

Matthieu Saada (M)

Centre Hospitalier de Perpignan, Infectious Diseases Unit, Perpignan, France.

Sarah Stabler (S)

University Lille, Centre National de la Recherche Scientifique Institut National de la Santé et de la Recherche Médicale Lille, Lille, France; Institut Pasteur de Lille, U1019 - Unité Mixte de Recherche 9017 - Center for Infection and Immunity of Lille, Lille, France.

Alexandre Alanio (A)

Institut Pasteur, Paris Cité University, National Reference Center for Invasive Mycoses and Antifungals, Translational Mycology Research Group, Mycology Department, Paris, France; Laboratoire de Parasitologie-Mycologie, AP-HP, Hôpital Saint-Louis, Paris, France.

Fanny Lanternier (F)

Institut Pasteur, Paris Cité University, National Reference Center for Invasive Mycoses and Antifungals, Translational Mycology Research Group, Mycology Department, Paris, France; Paris Cité University, Necker-Enfants Malades University Hospital, Necker-Pasteur Center for Infectious Diseases and Tropical Medicine, Assistance Publique-Hôpitaux de Paris, Institut Hospitalo Universitaire Imagine, Paris, France.

Guillaume Desoubeaux (G)

Centre Hospitalo-Universitaire Régional de Tours, Department of Parasitology-Mycology-Tropical Medicine, Tours, France. Electronic address: guillaume.desoubeaux@univ-tours.fr.

Classifications MeSH